Latest news with #Orchid
CNBC
6 days ago
- Business
- CNBC
This start-up is lowering the chances of passing on life-threatening diseases to your children—but it will cost you
Biotech start-up Orchid is one of the few companies offering in-vitro fertilisation (IVF) patients the option to screen their embryos for severe genetic diseases before their pregnancy begins. "This technology is going to totally reshape how people have children," Orchid's CEO Noor Siddiqui told CNBC's The Edge in an interview. "I think it's going to become an option that more and more people will choose because there's just the opportunity to avoid a lot of catastrophic outcomes, and they don't want to roll the dice on their child's health," Siddiqui added. During IVF, a woman takes fertility hormones to suppress her natural menstrual cycle and increase the number of eggs in her ovaries. Once her eggs are collected, they are mixed with the sperm and fertilized in a lab. The viable embryos are then transferred to the uterus. Siddiqui says that Orchid has developed a new technology that sequences 99% of an embryo's entire genome before implantation in the womb and screens for over 1,200 monogenic conditions, as well as some polygenic diseases. "When you have an embryo sample, you have about 125 cells on day five, and the embryologist at the IVF lab sends us about five of those cells, and in those five cells, you only have about 10,000 times less than the amount of DNA that you would have in a blood or saliva sample. So, what we had to invent is a new amplification protocol, as well as a new computational pipeline," Siddiqui said. The embryo screening process takes between two and three weeks, after which patients receive a whole genome embryo report. Orchid's counselors go through the report and help patients decide which embryo to move forward. Despite having been cleared by the Federal Drug Administration as a laboratory developed test (LDT) and backed by geneticists like George Church and Carlos Bustamante, Orchid's procedure has failed to convince some. "These tests, in general, cost money, often not covered by insurance. And so increasingly, breast cancer, for instance, is becoming more a disease of the poor because people can afford to undergo IVF and screen out breast cancer mutations when they've had a family history of breast cancer. I think that raises a problem ethically," bioethicist and Columbia University professor Robert Klitzman told The Edge in an interview. Orchid currently charges $2,500 per embryo screening. That's in addition to the IVF process which, according to the U.S. Department of Health and Human Services, ranges from $15,000 to $20,000 for a single cycle and sometimes requires several attempts. To mitigate the costs, the company has a philanthropic program that patients on low incomes can apply for. Orchid's technology is now available nationwide in the U.S. except in New York state, where Orchid had applied for a license to operate at the time of the interview. Learn more about Orchid's technology by clicking the video above. IVF was conceived as a reproductive method for people with infertility issues, but over the past decade, other patient groups have turned to it to prevent passing on genetic conditions to their child.
Business Standard
28-04-2025
- Business
- Business Standard
Kamat Hotels Q4 PAT surges 416% YoY to Rs 11 cr
Kamat Hotels (India) reported a 415.96% surge in consolidated net profit to Rs 10.99 crore on a 9.41% rise in revenue from operations to Rs 92.46 crore in Q4 FY25 over Q4 FY24. Profit before tax stood at Rs 16.19 crore in Q4 FY25, registering a growth of 96.96% from Rs 8.22 crore recorded in Q4 FY24. Total expenses declined 3.56% year on year to Rs 78.25 crore in Q4 FY25. Employee benefit expense stood at Rs 18.71 crore (up 8.21% YoY), while finance costs were at Rs 5.26 crore (down 64.72% YoY) during the period under review. On a full-year basis, the company's net profit jumped 3.32% to Rs 46.63 crore on a 19.1% rise in revenue to Rs 362.49 crore in FY24 over FY23. Kamat Hotels (India) operates a diverse portfolio of luxury and mid-premium hotels across India. Their brands include the "Orchid" chain, along with Fort JadhavGadh, Mahodadhi Palace, Lotus Resorts, and IRA by Orchid. The company focuses on continuous property improvement and expansion, primarily utilizing lease agreements, revenue sharing, and management contracts for growth. The scrip declined 2.72% to close at Rs 268.25 on Friday, 25 April 2025.
Business Standard
26-04-2025
- Business
- Business Standard
Kamat Hotels Q4 PAT surges 412% YoY to Rs 11 cr
Kamat Hotels (India) reported a 412.09% surge in consolidated net profit to Rs 11.01 crore on a 9.41% rise in revenue from operations to Rs 92.46 crore in Q4 FY25 over Q4 FY24. Profit before tax stood at Rs 16.19 crore in Q4 FY25, registering a growth of 96.96% from Rs 8.22 crore recorded in Q4 FY24. Total expenses declined 3.56% year on year to Rs 78.25 crore in Q4 FY25. Employee benefit expense stood at Rs 18.71 crore (up 8.21% YoY), while finance costs were at Rs 5.26 crore (down 64.72% YoY) during the period under review. On a full-year basis, the company's net profit jumped 3.32% to Rs 46.63 crore on a 19.1% rise in revenue to Rs 362.49 crore in FY24 over FY23. Kamat Hotels (India) operates a diverse portfolio of luxury and mid-premium hotels across India. Their brands include the "Orchid" chain, along with Fort JadhavGadh, Mahodadhi Palace, Lotus Resorts, and IRA by Orchid. The company focuses on continuous property improvement and expansion, primarily utilizing lease agreements, revenue sharing, and management contracts for growth. The scrip declined 2.72% to close at Rs 268.25 on Friday, 25 April 2025.
Yahoo
08-04-2025
- Business
- Yahoo
Orchid Island Capital to Announce First Quarter 2025 Results
VERO BEACH, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Orchid Island Capital, Inc. (NYSE:ORC) ("Orchid' or the "Company"), a real estate investment trust ("REIT"), today announced that it will release results for the first quarter of 2025 following the close of trading on the New York Stock Exchange on Thursday, April 24, 2025. Earnings Conference Call Details An earnings conference call and live audio webcast will be hosted Friday, April 25, 2025, at 10:00 AM ET. Participants can register and receive dial-in information at live audio webcast of the conference call can be accessed at or via the investor relations section of the Company's website at An audio archive of the webcast will be available for 30 days after the call. About Orchid Island Capital, Inc. Orchid Island Capital, Inc. is a specialty finance company that invests on a leveraged basis in Agency RMBS. Our investment strategy focuses on, and our portfolio consists of, two categories of Agency RMBS: (i) traditional pass-through Agency RMBS, such as mortgage pass-through certificates issued by Fannie Mae, Freddie Mac or Ginnie Mae and CMOs, and (ii) structured Agency RMBS. Orchid is managed by Bimini Advisors, LLC, a registered investment adviser with the Securities and Exchange Commission. CONTACT:Orchid Island Capital, E. Cauley, 772-231-1400Chairman and Chief Executive Officerhttps:// in to access your portfolio
Yahoo
10-03-2025
- Entertainment
- Yahoo
Katie Holmes Abandons Ballet Flats for Gilded Zimmermann Orchid Sandals at the Brand's Fall 2025 Show In Paris
Katie Holmes attended Zimmermann's fall 2025 show held on Sunday during Paris Fashion Week. The 'Batman Begins' star sat front row in a pair of gilded sandal heels hailing from Zimmermann's spring 2024 collection. Currently retailing for $725, the delicate Orchid style features statement-making metallic gold leather uppers accompanied by open square toes and intersecting thin straps that travel up the foot and around the ankles, kept in place with gold adjustable buckle closures. More from Footwear News Victoria and David Beckham's Daughter Harper Wears Cushy Slides for Mom's Fall 2025 Show In Paris Katie Holmes Takes a Jaunt in New York Wearing Ecco Biom 2.2 Sneaker Blooming gold orchid accents adorn the front of the shoes in clusters, imparting a dainty and whimsical quality. Finally, 3.3-inch sculptural stiletto heels round out the set, offering a subtle and walkable boost. Holmes' footwear pick is currently available in a range of sizing options on the designer brand's website. Accompanying her floral footwear, the 'First Daughter' actress sported a butter yellow oversized jacket that sat off the shoulders, layered over a brown top of some kind. On the bottom, Holmes sported equally baggy cargo pants with gold accents and turtleshell buttons. On the accessories front, the thespian toted a brown leather bucket bag partnered with gold jewelry. Holmes is best known for her classic 'everywoman' style, often re-wearing beloved pieces year-round. On the footwear front, the 'All We Had' director keeps her selections classic with Veja and Adidas sneakers, Gucci loafers, ballet flats and Bottega Veneta mules. Holmes is particularly fond of Adidas' Samba style, having been spotted in the on-trend silhouette on numerous occasions. Beyond her sharp off-duty shoes, Holmes' ties to the fashion industry have also earned her an Olay brand ambassador title. The thespian has also starred in campaigns for Bobbi Brown Cosmetics, Miu Miu and Ann Taylor. Adding to her impressive fashion resume, Holmes was also the co-founder of the fashion line Holmes & Yang, which she launched with her then-stylist Jeanne Yang, from 2011 to 2014. Katie Holmes' Red Carpet Shoe Style Through the Years [Photos] View Gallery28 Images Launch Gallery: Katie Holmes' Red Carpet Shoe Style Through the Years [Photos] Best of Footwear News Zoe Saldaña's Shoe Style Through the Years [PHOTOS] Mikey Madison's Elegant Red Carpet Shoe Style [PHOTOS] Kamala Harris' Best Footwear Moments Through the Years [PHOTOS]
